70 related articles for article (PubMed ID: 10457271)
1. Alendronate increases bone density and bone strength at the distal radius in postmenopausal women.
Schneider PF; Fischer M; Allolio B; Felsenberg D; Schröder U; Semler J; Ittner JR
J Bone Miner Res; 1999 Aug; 14(8):1387-93. PubMed ID: 10457271
[TBL] [Abstract][Full Text] [Related]
2. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
3. [The effect of a one-year alendronate therapy on postmenopausal osteoporosis. (Results in Hungary of an international multicenter clinical study)].
Bettembuk P; Balogh A
Orv Hetil; 1999 Dec; 140(50):2799-803. PubMed ID: 10647267
[TBL] [Abstract][Full Text] [Related]
4. Site-specific effects of strength training on bone structure and geometry of ultradistal radius in postmenopausal women.
Adami S; Gatti D; Braga V; Bianchini D; Rossini M
J Bone Miner Res; 1999 Jan; 14(1):120-4. PubMed ID: 9893073
[TBL] [Abstract][Full Text] [Related]
5. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
6. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
8. Prevention of bone loss in paraplegics over 2 years with alendronate.
Zehnder Y; Risi S; Michel D; Knecht H; Perrelet R; Kraenzlin M; Zäch GA; Lippuner K
J Bone Miner Res; 2004 Jul; 19(7):1067-74. PubMed ID: 15176988
[TBL] [Abstract][Full Text] [Related]
9. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
[TBL] [Abstract][Full Text] [Related]
10. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.
Bouxsein ML; Parker RA; Greenspan SL
Osteoporos Int; 1999; 10(6):505-9. PubMed ID: 10663352
[TBL] [Abstract][Full Text] [Related]
11. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Ozdemir F; Rodoplu M
Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
[TBL] [Abstract][Full Text] [Related]
12. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.
Ascott-Evans BH; Guanabens N; Kivinen S; Stuckey BG; Magaril CH; Vandormael K; Stych B; Melton ME
Arch Intern Med; 2003 Apr; 163(7):789-94. PubMed ID: 12695269
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
14. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
15. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.
Hochberg MC; Ross PD; Black D; Cummings SR; Genant HK; Nevitt MC; Barrett-Connor E; Musliner T; Thompson D
Arthritis Rheum; 1999 Jun; 42(6):1246-54. PubMed ID: 10366118
[TBL] [Abstract][Full Text] [Related]
16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
17. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
[TBL] [Abstract][Full Text] [Related]
18. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
19. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
[TBL] [Abstract][Full Text] [Related]
20. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]